Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis

BACKGROUND: Tumor necrosis factor inhibitors (TNFi) are common second-line treatments for rheumatoid arthritis (RA). This study was designed to compare the real-world clinical and economic outcomes between patients with RA who responded to TNFi therapy and those who did not. METHODS: For this retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Grabner, Michael, Boytsov, Natalie N., Huang, Qing, Zhang, Xiang, Yan, Tingjian, Curtis, Jeffrey R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433023/
https://www.ncbi.nlm.nih.gov/pubmed/28506320
http://dx.doi.org/10.1186/s13075-017-1293-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433023/
https://www.ncbi.nlm.nih.gov/pubmed/28506320
http://dx.doi.org/10.1186/s13075-017-1293-1

Ejemplares similares